Abstract
Effective therapies exist for the treatment of both vaginal trichomoniasis and bacterial vaginosis
(BV). Recurrent trichomonas infection is uncommon, and significant metronidazole resistance
remains rare. The management of metronidazole-resistant trichomoniasis is dependent on susceptibility
studies, which can be used to guide higher doses of metronidazole therapy. Recurrent BV is
common. A mechanism for reestablishing the normal vaginal flora with